Reducing Opioid Morbidity and Mortality
|ADM Brett Giroir, M.D., Assistant Secretary for Health|
|Elinore F. McCance-Katz, M.D., Ph.D., Assistant Secretary for Mental Health and Substance Use|
|Francis S. Collins, M.D., Ph.D., Director of the National Institutes of Health|
Deputy Goal Leaders:
Christopher M. Jones, Pharm.D., M.P.H., Substance Abuse and Mental Health Services Administration
Nora D. Volkow, M.D., National Institute on Drug Abuse
Reduce opioid-related morbidity and mortality through: 1) improving access to prevention, treatment and recovery support services; 2) targeting the availability and distribution of overdose-reversing drugs; 3) strengthening public health data and reporting; 4) supporting cutting-edge research; and 5) advancing the practice of pain management.
Starting from the baseline of September 30, 2017, by September 30, 2019:
- Reduce opioid prescribing as measured by morphine milligram equivalents (MME):
- Decrease by 25% the MME of opioid analgesics dispensed in U.S. outpatient retail pharmacies
- Decrease by 10% the morphine milligram equivalents (MME) in opioid analgesic prescriptions dispensed in U.S. outpatient retail pharmacies.
- Increase naloxone access:
- Increase by 30% the number of prescriptions dispensed for naloxone in U.S. outpatient retail pharmacies.
- Increase uptake of medications for the treatment of opioid use disorder:
- Increase by 25% the number of unique patients receiving prescriptions for buprenorphine in U.S. outpatient retail pharmacies (excluding implantable or long-acting injection products).
- Increase by 100% the number of prescriptions for long-acting injectable or implantable buprenorphine from retail, long-term care, and mail-order pharmacies in the U.S.
- Increase by 25% the number of prescriptions for extended-released naltrexone from retail, long-term care, and mail-order pharmacies in the U.S.
Goal Action Plans & Progress Updates